Renovacor (Renovacor) Research & Development : $23.99 Mil (TTM As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Renovacor Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Renovacor's Research & Development for the three months ended in Sep. 2022 was $7.42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 was $23.99 Mil.

Renovacor Research & Development Historical Data

The historical data trend for Renovacor's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor Research & Development Chart

Renovacor Annual Data

Trend

Dec20

Dec21

Research & Development

2.43

11.76

Renovacor Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Research & Development	Get a 7-Day Free Trial				2.93	4.34	5.93	6.29	7.42

Renovacor Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.99 Mil.

Renovacor (AMEX:RCOR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Renovacor Research & Development Related Terms

Thank you for viewing the detailed overview of Renovacor's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Renovacor (Renovacor) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 8142, Greenwich, CT, USA, 06836

Website

https://www.renovacor.com

Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Executives

Joseph S Carroll	officer: Chief Accounting Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino	director	C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr.	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll	officer: Chief Financial Officer
Jonas Grossman	director	17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa	director	17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook	director, officer: Chief Executive Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen	officer: Chief Scientific Officer	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd.	10 percent owner	C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong	10 percent owner	C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran	officer: Chief Medical Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco	officer: Interim CFO